Biopharma Antibody Immunotherapy Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma Antibody Immunotherapy Therapeutics
1.1 - About Biopharma Antibody Immunotherapy Therapeutics sector
Companies in Biopharma Antibody Immunotherapy Therapeutics discover, develop, and commercialize antibody-based medicines that harness the immune system to treat cancer and immune-mediated diseases. They deliver validated therapeutic candidates, clinical-stage assets, and marketed biologics with precise targeting, improved safety, and durable responses. Strategic buyers gain access to scalable antibody platforms, late-stage pipelines, and immuno-oncology franchises that can accelerate growth and diversify portfolios.
These companies build monoclonal and bispecific antibodies, T‑cell engagers, and antibody‑drug conjugates using proprietary linker–payload chemistries, alongside immune checkpoint inhibitors enhanced through Fc and glycoengineering. Discovery engines span phage and yeast display libraries, single B‑cell cloning, and AI‑guided epitope mapping, supported by translational biomarkers and companion diagnostics. They also offer preclinical pharmacology, CMC and GMP biologics manufacturing, and global clinical development across oncology and inflammatory indications.
They serve oncology centers and hospital systems through approved and investigational therapies, partner with biopharma companies via licensing and co‑development, and work with payers to secure reimbursement. Outcomes include expanded treatment options for difficult‑to‑treat cancers, higher response and survival rates, reduced toxicity versus chemotherapy, and faster time‑to‑market for partnered assets, strengthening market access and revenue durability.
2. Buyers in the Biopharma Antibody Immunotherapy Therapeutics sector
2.1 Top strategic acquirers of Biopharma Antibody Immunotherapy Therapeutics companies
Kodiak Sciences
- Description: Provider of clinical-stage biopharmaceutical research that engineers and develops next-generation retinal therapeutics. Using its ABC Platform to combine antibody and chemistry-based modalities, the company creates long-duration medicines aimed at preventing and treating high-prevalence retinal vascular and inflammatory diseases that lead to blindness.
- Key Products:
- Tarcocimab: Novel anti-VEGF antibody biopolymer conjugate in late-stage trials that delivers extended-durability treatment for high-prevalence retinal vascular diseases, reducing injection frequency
- KSI-501: First-in-class bispecific anti-IL-6/VEGF-trap antibody biopolymer conjugate that blocks IL-6-driven inflammation and VEGF-mediated angiogenesis to improve efficacy and durability in retinal disorders
- KSI-101: Bispecific anti-IL-6/VEGF-trap protein designed for macular edema and other retinal inflammatory diseases, targeting dual disease pathways for superior outcomes
- ABC Platform: Molecular-engineering platform that fuses antibody and chemistry-based technologies to create long-lasting, multi-functional retinal therapeutics and embed additional small-molecule actives for multifactorial eye diseases.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma Antibody Immunotherapy Therapeutics sector
M&A buyer group 1: Cancer Immunotherapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma Antibody Immunotherapy Therapeutics sector
3.1 - Buyout funds in the Biopharma Antibody Immunotherapy Therapeutics sector
2.2 - Strategic buyer groups for Biopharma Antibody Immunotherapy Therapeutics sector
4 - Top valuation comps for Biopharma Antibody Immunotherapy Therapeutics companies
4.2 - Public trading comparable groups for Biopharma Antibody Immunotherapy Therapeutics sector
Valuation benchmark group 1: Monoclonal Antibody Drug Developers
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.